Cytokinetics (NASDAQ:CYTK) Posts Quarterly Earnings Results

Key Points

• Cytokinetics beat revenue expectations with $19.36M in Q1 (vs. ~$8.5M consensus) and reported strong early U.S. uptake for MYQORZO—$4.8M net product revenue in a partial quarter, ~680 patients prescribed by quarter‑end (1,100 through April) and >275 HCP prescribers—helping drive a sharp share rally to $77.09.
• Topline Phase‑3 results for ACACIA‑HCM (aficamten) met both co‑primary endpoints with no new safety signals, prompting plans to engage regulators and pursue a supplemental NDA for non‑obstructive HCM alongside ongoing international filings and approvals.
• Financially, Q1 net loss widened to $206M, cash and investments fell to about $1.1B after ~$144M use and SG&A rose to $104.9M due to launch costs, and the company announced a planned $650M underwritten stock offering that presents near‑term dilution risk.

Cytokinetics (NASDAQ:CYTK - Get Free Report) issued its earnings results on Tuesday. The biopharmaceutical company reported ($1.67) EPS for the quarter, hitting the consensus estimate of ($1.67), FiscalAI reports. The business had revenue of $19.36 million during the quarter, compared to analyst estimates of $8.52 million. The business's quarterly revenue was up 1112.5% on a year-over-year basis. During the same period last year, the business earned ($1.36) EPS.

Here are the key takeaways from Cytokinetics' conference call:

• MYQORZO U.S. launch exceeded expectations in a partial quarter with $4.8M net product revenue, ~680 patients prescribed by quarter-end (1,100 through April), and >275 unique HCP prescribers, supporting early commercial momentum.
• Top-line results from ACACIA‑HCM (aficamten) met both co‑primary endpoints (KCCQ and peak VO2) with statistically significant treatment effects and no new safety signals, prompting plans to engage regulators and pursue a supplemental NDA for NHCM.
• Q1 net loss widened to $206M (vs. $161M year‑ago), cash and investments declined to ~$1.1B after ~$144M use in the quarter, and SG&A rose to $104.9M due to commercial launch costs, though full‑year expense guidance was maintained.
• Rapid global commercialization and regulatory progress — EU approval with a Germany launch planned in Q2, FDA acceptance of the MAPLE‑HCM sNDA (PDUFA 11/14/2026), plus ongoing MAA submissions (Switzerland, Canada) and partner progress in APAC — support international growth plans.

Cytokinetics Price Performance

Shares of CYTK traded up $11.04 during trading hours on Tuesday, hitting $77.09. The stock had a trading volume of 18,074,833 shares, compared to its average volume of 1,670,310. The stock has a market capitalization of $9.58 billion, a price-to-earnings ratio of -11.81 and a beta of 0.38. Cytokinetics has a 52 week low of $29.31 and a 52 week high of $80.20. The company's fifty day moving average is $64.00 and its two-hundred day moving average is $63.63.

More Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Topline Phase‑3 win — the ACACIA‑HCM pivotal trial of aficamten met both dual primary endpoints with supportive secondary data, a major de‑risking event that expands the drug’s commercial and regulatory potential. ACACIA‑HCM Topline Results
• Positive Sentiment: Strong initial commercial uptake — management reported U.S. launch demand for MYQORZO with ~275 HCPs prescribing to an estimated ~680 patients in Q1 and ~$4.8M in partial‑quarter net product revenue; company also reported ~ $1.1B in cash, which supports launch and development. Q1 2026 Financial Results & Business Update
• Positive Sentiment: Analyst upgrades — Needham (and other firms) raised price targets, increasing buy‑side enthusiasm and providing upward analyst momentum for shares. Analyst Price Target Raises
• Neutral Sentiment: Q1 reported EPS loss of ($1.67) matched expectations while revenue materially beat consensus ($19.36M vs ~$8.5M), signaling revenue strength but continued GAAP losses as the company scales launch and development. Q1 Loss, Revenue Beat
• Neutral Sentiment: Insider sales disclosed — EVP Andrew Callos and EVP Fady Malik sold shares under pre‑arranged Rule 10b5‑1 plans (large planned disposals rather than ad‑hoc exits); commonly viewed as neutral but can prompt short‑term investor attention. Malik SEC Form 4 Callos SEC Form 4
• Negative Sentiment: Planned $650M underwritten common stock offering — while proceeds would fund commercialization and development, the offering presents near‑term dilution risk that can weigh on the share price until completed. Proposed Public Offering

Wall Street Analysts Forecast Growth

CYTK has been the topic of several research reports. Wells Fargo & Company initiated coverage on Cytokinetics in a research report on Friday, April 10th. They issued an "overweight" rating and a $95.00 target price on the stock. JPMorgan Chase & Co. raised their target price on Cytokinetics from $74.00 to $75.00 and gave the company an "overweight" rating in a report on Tuesday, March 17th. UBS Group boosted their price objective on shares of Cytokinetics from $61.00 to $69.00 and gave the stock a "neutral" rating in a report on Friday, March 6th. Leerink Partners reiterated an "outperform" rating on shares of Cytokinetics in a research report on Tuesday, March 10th. Finally, Jefferies Financial Group restated a "buy" rating and issued a $90.00 target price on shares of Cytokinetics in a research note on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Cytokinetics has an average rating of "Moderate Buy" and an average target price of $92.10.

Insider Transactions at Cytokinetics

In related news, EVP Andrew Callos sold 26,000 shares of the firm's stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $61.87, for a total transaction of $1,608,620.00. Following the completion of the sale, the executive vice president directly owned 50,440 shares of the company's stock, valued at $3,120,722.80. This trade represents a 34.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Robert I. Blum sold 36,601 shares of the firm's stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $62.15, for a total value of $2,274,752.15. Following the completion of the sale, the chief executive officer owned 430,330 shares of the company's stock, valued at approximately $26,745,009.50. This trade represents a 7.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 184,976 shares of company stock valued at $11,639,319 in the last three months. 2.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Coldstream Capital Management Inc. bought a new position in Cytokinetics in the third quarter valued at about $261,000. CIBC Private Wealth Group LLC raised its holdings in Cytokinetics by 6.9% during the 4th quarter. CIBC Private Wealth Group LLC now owns 3,723 shares of the biopharmaceutical company's stock worth $237,000 after purchasing an additional 239 shares during the last quarter. &PARTNERS bought a new stake in Cytokinetics during the 4th quarter worth about $231,000. Pennington Partners & CO. LLC acquired a new position in Cytokinetics during the 4th quarter valued at about $208,000. Finally, Inceptionr LLC acquired a new stake in shares of Cytokinetics during the 3rd quarter worth approximately $204,000.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company's most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.